Page last updated: 2024-12-05

4-sulfanilic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-sulfanilic acid: minor descriptor (75-82); online search SULFANILIC ACIDS; Index Medicus search BENZENESULFONATES [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-aminobenzenesulfonic acid : An aminobenzenesulfonic acid that is aniline sulfonated at the para-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8479
CHEMBL ID1566888
CHEBI ID27500
SCHEMBL ID24407
MeSH IDM0262394

Synonyms (106)

Synonym
AC-12565
benzenesulfonic acid, 4-amino-
aniline-p-sulfonic acid
aniline-4-sulfonic acid
sulphanilic acid
nsc-7170
aniline-p-sulphonic acid
nsc7170
sulfanilsaeure
CHEBI:27500 ,
p-aminophenylsulfonic acid
inchi=1/c6h7no3s/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4h,7h2,(h,8,9,10
NCGC00090886-01
ccris 4576
einecs 204-482-5
4-sulfanilic acid
hsdb 5590
sulfanilsaeure [german]
nsc 7170
kyselina sulfanilova [czech]
ai3-15414
121-57-3
p-aminobenzenesulfonic acid
sulfanilic acid
C06335
4-aminobenzenesulfonic acid
sulfanilic acid, acs reagent, 99%
NCGC00090886-02
sulfanilic acid, >=99.0%
sulfanilic acid, puriss. p.a., >=99.0% (t)
AKOS000118732
BMSE000726
p-sulfoaniline-d4
S0120
p-anilinesulfonic acid
4-sulfoaniline
STK661383
BBL011603
sufanilic acid
4-aminobenzenesulphonic acid
p-sulfanilic acid
FT-0674701
kyselina sulfanilova
unii-434z8c2635
434z8c2635 ,
ec 204-482-5
97675-28-0
71949-32-1
EPITOPE ID:122241
AM91128
bdbm50443531
sulfanilic acid [mi]
sulfanilic acid [usp-rs]
4-aminophenylsulfonic acid
sulfamethoxazole impurity d [ep impurity]
sulfanilic acid [hsdb]
1-aminobenzene-4-sulfonic acid
sulfadimethoxine sodium for veterinary use impurity d [ep impurity]
sulfadiazine impurity b [ep impurity]
sulfadimethoxine impurity d [ep impurity]
sulfadimidine impurity f [ep impurity]
mesalazine impurity o [ep impurity]
p-sulfoaniline
4-aminobenzene-sulfonic acid
p-sulphanilic acid
p-aminobenzene sulfonic acid
p-aminobenzenesulphonic acid
SCHEMBL24407
CHEMBL1566888 ,
4-amino benzenesulphonic acid
sulfanilic acid;
DTXSID6024464 ,
mfcd00007886
J-004536
F0001-0346
4-aminobenzene-1-sulfonic acid
4-aminobenzene sulfonic acid
sulfanilic acid, 99%
sulfanilic acid, 99.0-100.5%, suitable for determination of nitroxide
nitrate reagent b, for microbiology
sulfanilic acid, jis special grade, 99.0-100.5%
sulfanilic acid, united states pharmacopeia (usp) reference standard
sulfanilic acid, pharmaceutical secondary standard; certified reference material
sulfanilic acid, vetec(tm) reagent grade, 99%
sulfanilic acid, p.a., 98.0-102.0%
4-aminobenzenesulphonic acid (sulphanilic acid)
sulfanilic acid, 98%, tech.
VS-02984
Q253746
EN300-19269
4-aminobenzenesulfonic acid 100 microg/ml in methanol
benzenesulfonic acid,4-amino-,diazotized,coupled with dyer's mulberry extract
E80415
sulfanilic acid [for biochemical research]
U0107
sulfadimethoxine sodium for veterinary use impurity d (ep impurity)
sulfadimidine impurity f (ep impurity)
para-aniline sulfonic acid
sulfadiazine impurity b (ep impurity)
sulfamethoxazole impurity d (ep impurity)
dtxcid604464
mesalazine impurity o (ep impurity)
sulfadimethoxine impurity d (ep impurity)
sulfanilic acid (usp-rs)
benzenesulfonic acid,4-amino-,diazotized,coupled with 5,5'-oxybis[1,3-benzenediol],sodium salt
Z104473374

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" These results indicate that after administration of these suppositories the bioavailability of non-absorbable drugs was sufficiently improved by enhancing both the release rate from the suppositories and the rectal membrane permeability."( Improvement by adjuvants on the rectal bioavailability of non-absorbable drugs following administration of suppository.
Masada, M; Nadai, T; Nakanishi, K, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
xenobiotic metaboliteAny metabolite produced by metabolism of a xenobiotic compound.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminobenzenesulfonic acidAny arenesulfonic acid that is benzenesulfonic acid substituted by at least one amino group at unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency22.38720.000214.376460.0339AID588532
pregnane X nuclear receptorHomo sapiens (human)Potency70.79460.005428.02631,258.9301AID720659
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5'-nucleotidaseRattus norvegicus (Norway rat)IC50 (µMol)70.10000.14000.78671.9000AID1055908
5'-nucleotidaseHomo sapiens (human)IC50 (µMol)8.20000.05002.24118.2000AID1055909
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
DNA metabolic process5'-nucleotidaseHomo sapiens (human)
leukocyte cell-cell adhesion5'-nucleotidaseHomo sapiens (human)
response to inorganic substance5'-nucleotidaseHomo sapiens (human)
response to ATP5'-nucleotidaseHomo sapiens (human)
ADP catabolic process5'-nucleotidaseHomo sapiens (human)
ATP metabolic process5'-nucleotidaseHomo sapiens (human)
adenosine biosynthetic process5'-nucleotidaseHomo sapiens (human)
negative regulation of inflammatory response5'-nucleotidaseHomo sapiens (human)
calcium ion homeostasis5'-nucleotidaseHomo sapiens (human)
inhibition of non-skeletal tissue mineralization5'-nucleotidaseHomo sapiens (human)
AMP catabolic process5'-nucleotidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
nucleotide binding5'-nucleotidaseHomo sapiens (human)
5'-deoxynucleotidase activity5'-nucleotidaseHomo sapiens (human)
protein binding5'-nucleotidaseHomo sapiens (human)
5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
zinc ion binding5'-nucleotidaseHomo sapiens (human)
identical protein binding5'-nucleotidaseHomo sapiens (human)
thymidylate 5'-phosphatase activity5'-nucleotidaseHomo sapiens (human)
IMP 5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
GMP 5'-nucleotidase activity5'-nucleotidaseHomo sapiens (human)
XMP 5'-nucleosidase activity5'-nucleotidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
plasma membrane5'-nucleotidaseHomo sapiens (human)
nucleoplasm5'-nucleotidaseHomo sapiens (human)
cytosol5'-nucleotidaseHomo sapiens (human)
plasma membrane5'-nucleotidaseHomo sapiens (human)
external side of plasma membrane5'-nucleotidaseHomo sapiens (human)
cell surface5'-nucleotidaseHomo sapiens (human)
membrane5'-nucleotidaseHomo sapiens (human)
extracellular exosome5'-nucleotidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1055903Cytotoxicity against HCEC after 24 hrs by sulforhodamine B assay2013European journal of medicinal chemistry, , Volume: 70Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
AID1055908Inhibition of rat recombinant ecto-5'-nucleotidase expressed in african green monkey COS7 cells using adenosine monophosphate as substrate preincubated for 10 mins before substrate addition measured after 10 mins by capillary electrophoresis2013European journal of medicinal chemistry, , Volume: 70Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
AID1055909Inhibition of human recombinant ecto-5'-nucleotidase expressed in african green monkey COS7 cells using adenosine monophosphate as substrate preincubated for 10 mins before substrate addition measured after 10 mins by capillary electrophoresis2013European journal of medicinal chemistry, , Volume: 70Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
AID1055905Cytotoxicity against human NCI-H157 cells at 100 uM after 24 hrs by sulforhodamine B assay2013European journal of medicinal chemistry, , Volume: 70Identification of sulfonic acids as efficient ecto-5'-nucleotidase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.13)18.7374
1990's2 (5.13)18.2507
2000's13 (33.33)29.6817
2010's22 (56.41)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.76 (24.57)
Research Supply Index3.69 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]